AC Immune, J&J deal

AC Immune and Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit partnered to develop and commercialize AC Immune’s ACI-35 to treat Alzheimer’s disease (AD). The companies also began a three-year ...